Boehringer Ingelheim bv
http://www.boehringer-ingelheim.nl
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Boehringer Ingelheim bv
Plenty Of Room For More Obesity Drugs, Says Boehringer, As Survodutide Enters Phase III
Boehringer Ingelheim is playing catch-up with Novo Nordisk and Lilly in obesity, but is hoping a higher dose and a more patient-friendly titration can help it prove that survodutide is a contender.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice